Zusammenfassung

Durch die Entwicklung einer Reihe von Antidepressiva, deren pharmakologische Wirkungen spezifischer und selektiver sind als die der älteren, klassischen trizyklischen Antidepressiva (TZA), entstand ein praktisches Verfahren zur Erforschung bestimmter Aspekte depressiver Erkrankungen. Man vermutete eine besondere Verbindung des Serotoninsystems zur Stimmungsregulation (van Praag 1972); die Entwicklung von Antidepressiva mit selektiver Wirkung auf Serotonin (5-HT) sollte einen Fortschritt in der Behandlung der Depression darstellen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Aberg-Wistedt A, Ross SB, Josteil KG et al (1982) A doubleblind study of zimelidine, a serotonin uptake inhibitor, and desipramine, a noradrenaline uptake inhibitor, in endogenous depression. Clinical and biochemical findings. Acta Psychiatr Scand 66:50–82PubMedCrossRefGoogle Scholar
  2. Agren H (1980) Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid. Suicide Psychiatr Res 2:225–236CrossRefGoogle Scholar
  3. Anora RC, Kregel L, Meitzer HY (1984) Seasonal variations of serotonin uptake in normal controls and depressed patients. Biol Psychiatry 19:795–804Google Scholar
  4. Asberg M, Bertilsson L, Tuck D et al (1973) Indolamine metabolites in the cerebrospinal fluid of depressed patients before and during treatment with nortriptyline. Clin Pharmacol Ther 14:277–286PubMedGoogle Scholar
  5. Asberg M, Thoren P, Traskman L, Bertilsson L, Ringberger W (1976a) Serotinin depression: a biochemical subgroup within the affective disorders? Science 191:478–490PubMedCrossRefGoogle Scholar
  6. Asberg M, Traskman L, Thoren P (1976b) 5-HI A A in the cerebrospinal fluid: a biochemical suicide predictor? Arch Gen Psychiatry 33:1193–1197PubMedCrossRefGoogle Scholar
  7. Banki CM (1977) Correlation of anxiety and related symptoms with cerebrospinal fluid. 5-hydroxyindoleacetic acid in depressed women. J Neural Transm 41:135–143PubMedCrossRefGoogle Scholar
  8. Banki CM, Arato M, Papp Z, Kurcz M (1984) Biochemical markers in suicidal patients investigations with cerebrospinal fluid amine metabolites and endocrine tests. J Affect Disord 6:341–350PubMedCrossRefGoogle Scholar
  9. Brown GL, Goodwin FK, Ballenger JC et al (1979) Aggression in humans correlates with cerebrospinal fluid amine metabolites. Psychol Res 1:131–139Google Scholar
  10. Brown GL, Ebert MH, Goyer PF et al (1982) Aggression suicide and serotonin: relationship to CSF amine metabolites. Am J Psychiatry 139:741–746PubMedGoogle Scholar
  11. Cassidy S, Henry J (1987) Fatal toxicity of antidepressant drugs in overdose. Br Med J 295:1021–1024CrossRefGoogle Scholar
  12. Cottraux J, Mollard E, Bouvard M et al (1990) A controlled study of fluvoxamine and exposure in obsessive-compulsive disorder. Int Clin Psychopharmacol 5:17–30PubMedCrossRefGoogle Scholar
  13. Cowdry RW, Gardner DL (1988) Pharmacotherapy of borderline personality disorder. Arch Gen Psychiatry 45:111–119PubMedCrossRefGoogle Scholar
  14. Cronholm B, Asberg A, Montgomery S, Schalling D (1977) Suicidal behavior syndrome with low CSF 5-HIAA. Br Med J 19:776CrossRefGoogle Scholar
  15. Den Boer JA, Westenberg GM (1988) Effects of serotonin and noradrenaline uptake inhibitors in panic disorders: a doubleblind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3:59–74CrossRefGoogle Scholar
  16. Evans L, Moore G (1981) The treatment of phobic anxiety by zimelidine. Acta Psychiatr Scand [Suppl 290] 61:342–345CrossRefGoogle Scholar
  17. Evans L, Kennardy J, Schneider P et al (1986) Effect of a selective serotonin uptake inhibitor in agoraphobia with panic attacks. Acta Psychiatr Scand 73:49–53PubMedCrossRefGoogle Scholar
  18. Fabre LF (1986) A study of paroxetine, imipramine and placebo in the treatment of depressed outpatients (Proceedings). CINP, MunichGoogle Scholar
  19. Gardner DL, Cowdry RJW (1985) Alprazolam-induced dyscontrol in borderline personality disorder. Am J Psychiatry 141:98–100Google Scholar
  20. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:55–62Google Scholar
  21. Lidberg L, Tuck JR, Asberg M, Scalia-Tomba GP, Bertilsson L (1985) Homicide, suicide and CSF 5-HIAA. Acta Psychiatr Scand 71:230–236PubMedCrossRefGoogle Scholar
  22. Linnoila M, Virkkunen M, Scheinin M et al (1984) Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behaviour. Life Sci 33:2609–2614CrossRefGoogle Scholar
  23. Lopez-Ibor JJ, Saiz-Ruiz J, Perez De Los Cobos JC (1985) Biological correlations of suicide and aggressivity in major depression with melancholia. Neuropsychobiology 14:67–74PubMedCrossRefGoogle Scholar
  24. Marks IM, Stern RS, Mawson D, Cobb J, McDonald R (1980) Clomipramine and exposure for obsessive rituals. Br J Psychiatry 136:1–25PubMedCrossRefGoogle Scholar
  25. Marks IM, Lelliott P, Basoglu M, Noshirvani H (1988) Clomipramine and exposure for compulsive rituals. Br J Psychiatry 152:522–534PubMedCrossRefGoogle Scholar
  26. Montgomery SA (1980) Clomipramine in obsessional neurosis, a placebo controlled trial. Pharm Med 1:189–192Google Scholar
  27. Montgomery SA (1989) The efficacy of fluoxetine as an antidepressant in the short and long term. Int Clin Psychopharmacol 4/s1: 113–119PubMedGoogle Scholar
  28. Montgomery SA (in press) 5-HT uptake inhibitors in the treatment of anxiety, agitation and suicidal thoughts. (Proceedings VHIth World Congress of Psychiatry, Athens 1989. Elsevier, Amsterdam)Google Scholar
  29. Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389PubMedCrossRefGoogle Scholar
  30. Montgomery SA, Pinder RM (1987) Do some antidepressants promote suicide? Psychopharmacology 92:265–266PubMedCrossRefGoogle Scholar
  31. Montgomery SA, Cronholm B, Asberg M, Montgomery D (1978) Differential effects on suicidal ideation of mianserin, maprotiline and amitriptyline. Br J Clin Pharmacol 5:77S-80SPubMedCrossRefGoogle Scholar
  32. Montgomery SA, McAuley R, Rani SJ, Roy D, Montgomery D (1981a) A double blind comparison of zimelidine and amitriptyline in endogenous depression. Acta Psychiatr Scand [Suppl 290] 63:314–327CrossRefGoogle Scholar
  33. Montgomery SA, Rani SJ, McAuley R, Roy D, Montgomery DB (1981b) The antidepressant efficacy of zimelidine and maprotiline. Acta Psychiatr Scand [Suppl 290] 63:219–224CrossRefGoogle Scholar
  34. Montgomery SA, James D, Montgomery DB (1987) Pharmacological specificity is not the same as clinical selectivity. In: Dahl S, Gram LF, Paul SM, Potter WZ (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York Tokyo (Psychopharmacology series 3)Google Scholar
  35. Montgomery SA, Montgomery D, Baldwin D, Green M (1989) Intermittent 3-day depressions and suicidal behaviour. Neuropsychobiology 22:128–134PubMedCrossRefGoogle Scholar
  36. Montgomery SA, Fineberg N, Baldwin D, Montgomery D (in press) 5HT uptake inhibitors in the treatment of anxiety, agitation and suicidal thoughts. Exerpta MedicaGoogle Scholar
  37. Muijen M, Roy D, Silverstone T, Mehmet A, Christie M (1988) A comparative clinical trial of fluoxetine, mianserin and placebo with depressed outpatients. Acta Psychiatr Scand 78:384–390PubMedCrossRefGoogle Scholar
  38. Muscettola G, Goodwin FK, Potter WZ et al (1978) Imipramine and desipramine in plasma and spinal fluid. Arch Gen Psychiatry 35:621–625PubMedCrossRefGoogle Scholar
  39. Ninan PT, Kaummen DP van, Scheinin M, Linnoila M, Bunney WE, Goodwin FK (1984) CSF 5-hydroxyindoleacetic acid in suicidal schizophrenic patients. Am J Psychiatry 141:566–569PubMedGoogle Scholar
  40. Post RM, Ballenger JC, Goodwin FK (1980) Cerebrospinal fluid studies of neurotransmitter function in manic and depressive illness. In: Wood JH (ed) Neurobiology of cerebrospinal fluid 1. Plenum, New York, pp 685–717CrossRefGoogle Scholar
  41. Praag HM van (1972) Significance of biochemical parameters in the diagnosis, treatment and prevention of depressive disorders. Biol Psychiatry 12:101–131Google Scholar
  42. Praag HM van (1977) New evidence of serotonin-deficient depressions. Neuropsychobiology 3:56–63PubMedCrossRefGoogle Scholar
  43. Praag HM van (1981) Central monoamines and the pathogenesis of depression. In: Praag HM van, Lader MH, Rafaelsen OJ (eds) Hand book of biological psychiatry. Part IV. Brain mechanisms and abnormal behaviour. Dekker, New York, pp 159–205Google Scholar
  44. Praag HM van (1982) Depression, suicide and metabolism of suicide in the brain. J Affect Disord 4:275–290PubMedCrossRefGoogle Scholar
  45. Praag HM van (1983) CSF 5-HIAA and suicide in non-depressed schizophrenics. Lancet 11:977–978CrossRefGoogle Scholar
  46. Praag HM van (1987) Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. J Affect Disord 13:1–8PubMedCrossRefGoogle Scholar
  47. Praag HM van, Korf J (1971) Endogenous depressions with and without disturbances of 5-hydroxytryptamine metabolism: a biochemical classification? Psychopharmacology 19:148–152CrossRefGoogle Scholar
  48. Rouillon F, Phillips R, Serrurier E, Ansart E, Gerard MJ (1989) Prophylactic efficacy of maprotiline on relapses of unipolar depression. Encephale XV/6:527–534Google Scholar
  49. Rydin E, Schalling D, Asberg M (1982) Rorschach ratings in depressed and suicidal patients with low CSF 5-HIAA. Psychiatry Res 7:229–243PubMedCrossRefGoogle Scholar
  50. Teicher MH, Glod C, Cole JO (1990) Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 147:207–210PubMedGoogle Scholar
  51. Traskman L, Asberg M, Bertilsson L et al (1979) Plasma levels of clorimipramine and its demethylmetabolite during treatment of depression. Differential biochemical and clinical effects of the two compounds. Clin Pharmacol Ther 26:600–610PubMedGoogle Scholar
  52. Traskman L, Asberg M, Bertilsson L, Sjostrand L (1981) Monoamine metabolites in cerebrospinal fluid and suicidal behaviour. Arch Gen Psychiatry 38:631–636PubMedCrossRefGoogle Scholar
  53. Traskman-Bendz L, Asberg M, Bertilsson L, Thoren P (1984) CSF monoamine metabolites of depressed patients during illness and after recovery. Acta Psychiatr Scand 69:333–342PubMedCrossRefGoogle Scholar
  54. Veaugh Geiss J de, Landau P, Katz R (1989) Treatment of obsessive compulsive disorder with clomipramine. Psychiatr Ann 19/2:97–101Google Scholar
  55. Wakelin J (1988) The role of serotonin in depression and suicide. Adv Biol Psychiatry 17:70–83Google Scholar
  56. Wilde J de, Mertens C, Fredricson Overo K, Hepfner Petersen HE (1985) Citalopram vs. mianserin, a controlled, double-blind trial in depressed patients. Acta Psychiatr Scand 72:89–96PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • Stuart Montgomery

There are no affiliations available

Personalised recommendations